恩韦肟 | 72301-79-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 恩韦肟
• 中文别名: (NE)-N-[(2-氨基-3-丙-2-基磺酰基苯并咪唑-5-基)-苯基亚甲基]羟胺
• 英文名称: enviroxime
• 英文别名: 1-isopropylsulfonyl-2-amino-6-(α-hydroxyiminobenzyl)benzimidazole；(NE)-N-[(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethylidene]hydroxylamine
• CAS: 72301-79-2；63198-97-0；72301-78-1
• 化学式: C₁₇H₁₈N₄O₃S
• 分子量: 358.421
• InChiKey: IWKXBHQELWQLHF-CAPFRKAQSA-N

物化性质

• 熔点：
  198-199°
• 沸点：
  607.2±61.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶，甲醇：加热时微溶

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-氨基-6-苯甲酰基-1-[(异丙基)磺酰基]-1H-苯并咪唑 生成 恩韦肟
  参考文献：
  名称：

  WIKEL J. H.; PAGEL C. J.; DELONG D. C.; NELSON J. D.; WU C. Y. E.; PASCHA+, J. MED. CHEM., 1980, 23, NO 4, 368-372

  摘要：

  DOI：

文献信息

• Immunosuppressive effects of pteridine derivatives
  申请人：——

  公开号：US20040077859A1

  公开（公告）日：2004-04-22

  This invention relates to a group of trisubstituted and tetrasubstituted pteridine derivatives, their pharmaceutically acceptable salts, N-oxides, solvates, dihydro- and tetrahydroderivatives and enantiomers, possessing unexpectedly desirable pharmaceutical properties, in particular which are highly active immunosuppressive agents, and as such are useful in the treatment in transplant rejection and/or in the treatment of certain inflammatory diseases. These compounds are also useful in preventing or treating cardiovascular disorders, allergic conditions, disorders of the central nervous system and cell proliferative disorders.

  这项发明涉及一组三取代和四取代的嘌呤衍生物，它们的药用盐、N-氧化物、溶剂化物、二氢和四氢衍生物及对映异构体，具有意想不到的、令人满意的药理性质，尤其是作为高度活性的免疫抑制剂，因此可用于治疗移植排斥反应和/或治疗某些炎症性疾病。这些化合物还用于预防或治疗心血管疾病、过敏性疾病、中枢神经系统疾病和细胞增殖紊乱。
• ANTIVIRAL 1,3-DI-OXO-INDENE COMPOUNDS
  申请人：Novartis AG

  公开号：US20210323947A1

  公开（公告）日：2021-10-21

  The invention provides compounds of Formula (I): as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

  这项发明提供了如下式（I）的化合物： 如本文所述，以及包含这些化合物的药用盐、含有这些化合物的药物组合物，以及治疗病毒感染的方法。
• INDANONE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS OR OPTICAL ISOMERS THEREOF, PREPARATION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING VIRAL DISEASES
  申请人：Jung Young Sik

  公开号：US20140114068A1

  公开（公告）日：2014-04-24

  Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

  揭示了新颖的茚酮衍生物，其药用盐或对映体，以及其制备方法和作为活性成分的用于预防或治疗病毒性疾病的药物组合物。这些茚酮衍生物对包括柯萨奇病毒、肠道病毒、回声病毒、脊髓灰质炎病毒和鼻病毒在内的小RNA病毒具有出色的抑制活性，并且具有低细胞毒性，因此它们可用作预防或治疗包括小儿麻痹症、瘫痪、急性出血性结膜炎、病毒性脑膜炎、手足口病、水疱病、甲型肝炎、肌炎、心肌炎、胰腺炎、糖尿病、流行性肌痛、脑炎、流感、手足口病、哮喘、慢性阻塞性肺病、肺炎、鼻窦炎或中耳炎等病毒性疾病的药物组合物的活性成分。
• [EN] HETEROCYCLIC ANTI-VIRAL COMPOUNDS COMPRISING METABOLIZABLE MOIETIES AND THEIR USES<br/>[FR] COMPOSES ANTIVIRAUX HETEROCYCLIQUES COMPORTANT DES GROUPES FONCTIONNELS METABOLISABLES ET LEURS UTILISATIONS
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2005097760A1

  公开（公告）日：2005-10-20

  The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, diheteroaryl- and mixed phenyl heteroaryl substituted five-membered heterocycle compounds, compositions comprising the compounds and the use of such compounds and compositions to inhibit HCV replication and/or proliferation as a therapeutic approach towards the treatment and/or prevention of HCV infections in humans and animals.

  本发明涉及替代前药及其组合物，用于治疗或预防丙型肝炎病毒（HCV）感染。具体而言，本发明涉及替代二苯基、二杂环芳基和混合苯基杂环芳基替代的五元杂环化合物的前药，包含这些化合物的组合物以及利用这些化合物和组合物来抑制HCV复制和/或增殖作为治疗方法，以治疗和/或预防人类和动物中的HCV感染。
• ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS
  申请人：NOVARTIS AG

  公开号：US20170275329A1

  公开（公告）日：2017-09-28

  The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions for treatment of viral infections, especially HRV.

  本发明提供了化合物I式或其盐；以及这些化合物的治疗用途。该发明还提供了包括这些化合物的药物组合物，以及包括这些化合物与治疗辅助剂的组合物，并且提供了使用这些化合物和组合物治疗病毒感染，特别是HRV的方法。